TABLE 4.
Landmark Analysis of the Risk of Clinical Endpoints for Patients With and Without DM Treated With >12 Months Versus ≤12 Months of Clopidogrel After an Index Percutaneous Coronary Revascularization With BMS*
| Events Clopidogrel Duration
|
Univariate
|
Multivariable Adjusted†
|
Propensity Adjusted‡
|
|||||
|---|---|---|---|---|---|---|---|---|
| ≤12 Months | >12 Months | HR | 95% CI | HR | 95% CI | HR | 95% CI | |
| DM treated with insulin | ||||||||
| Death | 190 (27) | 87 (25) | 0.89 | 0.69–1.15 | 0.78 | 0.60–1.02 | 0.90 | 0.69–1.16 |
| Death or MI | 208 (32) | 92 (30) | 0.88 | 0.69–1.13 | 0.79 | 0.61–1.02 | 0.87 | 0.67–1.12 |
| CABG or PCI | 88 (17) | 44 (18) | 0.97 | 0.67–1.39 | 0.95 | 0.66–1.39 | 0.87 | 0.60–1.27 |
| Stroke | 16 (3) | 6 (2) | 0.73 | 0.29–1.87 | 0.82 | 0.31–2.18 | 0.81 | 0.31–2.11 |
| Severe bleed | 27 (4) | 13 (4) | 0.90 | 0.46–1.74 | 0.77 | 0.39–1.54 | 0.88 | 0.45–1.73 |
|
| ||||||||
| DM, no insulin | ||||||||
| Death | 405 (15) | 179 (13) | 0.85 | 0.71–1.01 | 0.83 | 0.70–1.00 | 0.89 | 0.74–1.07 |
| Death or MI | 498 (19) | 228 (17) | 0.88 | 0.75–1.03 | 0.87 | 0.74–1.02 | 0.88 | 0.75–1.04 |
| CABG or PCI | 324 (15) | 171 (15) | 1.03 | 0.86–1.24 | 1.08 | 0.89–1.31 | 1.00 | 0.82–1.21 |
| Stroke | 53 (2) | 18 (1) | 0.65 | 0.38–1.11 | 0.68 | 0.39–1.19 | 0.69 | 0.40–1.19 |
| Severe bleed | 71 (3) | 31 (2) | 0.83 | 0.54–1.27 | 0.87 | 0.56–1.34 | 0.99 | 0.64–1.54 |
|
| ||||||||
| No DM | ||||||||
| Death | 526 (11) | 193 (10) | 0.86 | 0.73–1.02 | 0.84 | 0.71–1.00 | 0.89 | 0.75–1.06 |
| Death or MI | 711 (15) | 268 (14) | 0.88 | 0.77–1.02 | 0.86 | 0.75–1.00 | 0.88 | 0.76–1.02 |
| CABG or PCI | 474 (12) | 200 (12) | 1.03 | 0.87–1.21 | 1.08 | 0.91–1.28 | 0.97 | 0.81–1.15 |
| Stroke | 51 (1) | 18 (1) | 0.84 | 0.49–1.44 | 0.87 | 0.50–1.52 | 0.90 | 0.52–1.58 |
| Severe bleed | 100 (2) | 37 (2) | 0.86 | 0.59–1.25 | 0.90 | 0.61–1.33 | 0.92 | 0.62–1.37 |
Values are n (%) unless otherwise indicated.
*
Subjects free of the endpoint at 12 months were assessed for risk of the endpoint from 12 months to end of follow-up.
†
Adjusted for age, year of stenting, smoking, acute coronary syndrome during index admission, hypertension, peripheral vascular disease, heart failure, chronic kidney disease, warfarin at discharge, and myocardial infarction, stroke, revascularization, and bleeding during the 1 year after the index procedure.
‡
Adjusted for the propensity to use clopidogrel for >12 months.